Woodbury-based Kindeva Drug Delivery’s global health security division Meridian Medical Technologies, LLC was awarded a contract for up to $129 million to supply DuoDote® to the Strategic National Stockpile (SNS).

The drug would be used to treat nerve agent poisoning. The antidote autoinjector contains atropine and pralidoxime chloride for treatment of exposures to organophosphorus nerve agents as well as organophosphorus insecticides. 

In a news release, Kindra CEO Milton Boyer said, “Kindeva is a global force in medical countermeasure development, manufacturing and supply. As a trusted partner to the SNS, this contract underscores the ongoing importance of maintaining readiness against potential threats…Our long-standing partnership with the SNS reflects our commitment to national preparedness and our ability to deliver crucial medical countermeasures when they are needed most.”

Kindeva manufactures DuoDote® for distribution at strategic locations across the United States as part of the country’s emergency preparedness program protecting from chemical nerve agent attacks.